Javier Rejas - Concepedia

Author

Javier Rejas

Also Known As

J REJAS, J Rejas, J Rejas-Gutiérrez, J. REJAS, J. Rejas, J. Rejas-Gutiérrez, Javier Rejas, Javier Rejas Gutiérrez, Javier Rejas-Gutierrez, Javier Rejas-Gutiérrez

356

Publications

Citations

H-Index

118

Concepts

All Affiliations

Pfizer (Spain)Universitat de Barcelona Hospital Universitario de La Princesa Pfizer (United States)Universidad Autónoma de Madrid

About

Javier Rejas is an author at Pfizer (Spain) specializing in medicine, psychiatry, and psychopathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	47	2.6K
2	Health Sciences	12	12	583
3	Public Health	10	10	497
4	Nursing	3	3	141
5	Education	2	2	68

Javier Rejas

106

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool Javier Garcı́a-Campayo, Enric Zamorano, Miguel A. Ruíz, Health and Quality of Life Outcomes	2010	629
Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care Miguel A. Ruíz, Enric Zamorano, Javier Garcı́a-Campayo, Journal of Affective Disorders Psychological Co-morbiditiesPrimary CarePsychiatryComorbid Psychiatric DisorderRehabilitation	2010	294
Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice Julio Bobes, Celso Arango, Margarida García-García, The Journal of Clinical Psychiatry	2009	259
Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component Concepción Pérez, Rafael Gálvez, Silvia Huelbes, Health and Quality of Life Outcomes	2007	216
Frequency of Sexual Dysfunction and Other Reproductive Side-effects in Patients with Schizophrenia Treated with Risperidone, Olanzapine, Quetiapine, or Haloperidol: The Results of the EIRE Study Julio Bobes, M. P. GARC A-PORTILLA, Javier Rejas, Journal of Sex & Marital Therapy	2003	213
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study Julio Bobes, Celso Arango, P. Aranda, Schizophrenia Research PsychiatryPsychotic DisorderPsychotropic MedicationPsychopharmacologySchizophrenia	2006	196
Male Erectile Dysfunction and Health-Related Quality of Life José Juan Sánchez-Cruz, Andrés Cabrera‐León, Antonio Martín‐Morales, European Urology Quality Of LifeSexual HealthUrologyAndrologyErectile Dysfunction	2003	190
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort Julio Bobes, Celso Arango, Margarida García-García, Schizophrenia Research Tobacco ControlPsychiatryRisk PredictionAddictionHealthy Lifestyle Habits	2010	180
Development and Validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q)© Miguel A. Ruíz, Antonio Pardo, Javier Rejas, Value in Health Quality Of Life“ Treatment SatisfactionMedicines Questionnaire ”PsychiatryPatient-reported Outcome	2008	168
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study Julio Bobes, Javier Rejas, M. García-García, Schizophrenia Research PsychiatryPsychotic DisorderMedicinePsychotropic MedicationPsychopharmacology	2003	142

Page 1